1. Home
  2. LGVN vs CISS Comparison

LGVN vs CISS Comparison

Compare LGVN & CISS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGVN
  • CISS
  • Stock Information
  • Founded
  • LGVN 2014
  • CISS 2022
  • Country
  • LGVN United States
  • CISS Greece
  • Employees
  • LGVN N/A
  • CISS N/A
  • Industry
  • LGVN Medicinal Chemicals and Botanical Products
  • CISS Marine Transportation
  • Sector
  • LGVN Health Care
  • CISS Consumer Discretionary
  • Exchange
  • LGVN Nasdaq
  • CISS Nasdaq
  • Market Cap
  • LGVN 31.2M
  • CISS 8.6M
  • IPO Year
  • LGVN 2021
  • CISS N/A
  • Fundamental
  • Price
  • LGVN $3.17
  • CISS $1.30
  • Analyst Decision
  • LGVN Strong Buy
  • CISS
  • Analyst Count
  • LGVN 1
  • CISS 0
  • Target Price
  • LGVN $12.00
  • CISS N/A
  • AVG Volume (30 Days)
  • LGVN 11.3M
  • CISS 284.9K
  • Earning Date
  • LGVN 08-09-2024
  • CISS 08-30-2024
  • Dividend Yield
  • LGVN N/A
  • CISS N/A
  • EPS Growth
  • LGVN N/A
  • CISS N/A
  • EPS
  • LGVN N/A
  • CISS 48.19
  • Revenue
  • LGVN $978,000.00
  • CISS $38,379,148.00
  • Revenue This Year
  • LGVN $137.24
  • CISS N/A
  • Revenue Next Year
  • LGVN $50.77
  • CISS N/A
  • P/E Ratio
  • LGVN N/A
  • CISS $0.03
  • Revenue Growth
  • LGVN N/A
  • CISS N/A
  • 52 Week Low
  • LGVN $0.77
  • CISS $1.11
  • 52 Week High
  • LGVN $35.60
  • CISS $77.00
  • Technical
  • Relative Strength Index (RSI)
  • LGVN 54.46
  • CISS 39.53
  • Support Level
  • LGVN $2.90
  • CISS $1.35
  • Resistance Level
  • LGVN $4.88
  • CISS $1.55
  • Average True Range (ATR)
  • LGVN 0.74
  • CISS 0.08
  • MACD
  • LGVN -0.06
  • CISS 0.01
  • Stochastic Oscillator
  • LGVN 32.69
  • CISS 16.67

About LGVN Longeveron Inc.

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

About CISS C3is Inc.

C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.

Share on Social Networks: